Dr. Gary Pace has over 30 years of experience in the life science field, with 20 years of legal and corporate experience and 12 years in biotech research for large and small companies. He is a registered patent attorney with a record of over 40 issued US patents. Since 2001, Dr. Pace has helped many early and development stage companies in the life sciences with their strategic, intellectual property, and transactional activities. He has held executive management positions in several companies, including Novartis Corporation, Gentris Corporation, Quill Medical, Inc., and BASF Corporation. Dr. Pace has a J.D. degree from the School of Law at North Carolina Central University, and his Ph.D. is from North Carolina State University.
Scott McGinnis leads worldwide sales activities, including distributorships. He has 25 years of sales experience across leading companies in the life science industry, including Life Technologies, Thermo Fisher Scientific, Essen BioScience, and Sartorius, and expertise in building and leading teams selling instruments in the microscopy, flow cytometry, and bio-analytical fields. He joined Cell Microsystems from Sarcos Robotics, where he was Vice President of Sales through the company’s 2021 SPAC acquisition. Mr. McGinnis earned a B.A. in Chemistry from the College of Holy Cross.
Kap Kumar has over 25 years of experience in the life sciences tools and reagents industry. He started in R&D and product development where he launched products for cell biology and imaging applications. For the last 15 years, Kap has led strategic marketing, market development and product management for a variety of companies including Thermo Fisher Scientific (Life technologies), Danaher (Beckman Coulter life Sciences), Cell Signaling Technologies, Nexcelom Biosciences and Avantor-VWR. Kap has diverse experience managing complex portfolios including instruments, consumables, and reagents both in early stage and mature companies. Kap has a Ph.D. in Cell and Molecular Biology from Kent State University, a post doctorate from Harvard Medical School, and an MBA from Babson College.
Dr. Hartman has over 15 years of research and development experience in a range of disciplines, including oncology, stem cell biology, toxicology, and regenerative medicine in both academic and industry settings. She is focused on identifying and developing novel product applications for cellular and genomics workflows for the CellRaft Technology. She most recently served as the Director of Cell-Based Assay Development at ScitoVation. Dr. Hartman received a Ph.D. in Molecular Cancer Biology from Duke University and holds a Bachelor of Science degree in Biology from the University of Virginia.
Dr. Steven Gebhart has over 10 years of research and development experience in medical and life science product development, with an emphasis in optical imaging, spectroscopy, and interferometry. He most recently served as Manager of Product Development and Manufacturing at Oncoscope, Inc., where he served as principal investigator on multiple NIH and NSF Phase I, II, and IIB SBIR grant awards. Dr. Gebhart has a Ph.D. degree in biomedical engineering from Vanderbilt University, where he completed his doctoral work in the biomedical optics laboratory of Anita Mahadevan-Jansen, Ph.D. He also holds a Bachelor of Science degree from Duke University in biomedical engineering.
Rob McClellan leads Cell Microsystems’ efforts in software systems engineering for automated platforms that incorporate the CellRaft Technology. Rob’s professional experience covers 30 years in automation, image processing, software engineering, and research & development. After beginning his career conducting medical imaging research at Cornell University, he developed products in the high-speed paper handling industry at Pitney Bowes, General Binding and Bell + Howell. Most recently, he worked for Monsanto Company developing imaging applications for agricultural biotechnology research in automated greenhouses. He completed his Masters of Science in Electrical Engineering at the University of Rochester, and holds a Bachelor's of Science in Physics with a minor in Mathematics from the State University of New York at Albany
Lisa Birkby is a driven marketing professional with degrees in marketing, business management, and accounting. Mrs. Birkby has 15 years’ experience working with scientists to help convert complicated scientific messages into engaging content. Her desire is to help promote products that increase efficiency in the lab, leading to faster discoveries in research that will help improve the human condition.
Dr. Pace has been CEO at Cell Microsystems since 2014 and led the reboot of the Company to focus on product applications and automated instrumentation. He has over 30 years of experience in the life science field, with 20 years of legal and corporate experience and 12 years in biotech research for large and small companies. Dr. Pace is a registered patent attorney with a record of over 40 issued US patents. Since 2001 he has helped many early and development stage companies in the life sciences with their strategic, intellectual property, and transactional activities. Dr. Pace has held executive management positions in several companies, including Novartis Corporation, Gentris Corporation, Quill Medical, Inc., and BASF Corporation. Dr. Pace holds a J.D. degree from the School of Law at North Carolina Central University and his Ph.D. from North Carolina State University.
Dr. Lashkari, a co-founder of THP, has worked in the life sciences area developing and commercializing novel technologies for over 25 years. He gained experience as an entrepreneur and through senior management positions in a number of life science companies. He was a founding Research Director at Synteni, which was acquired by Incyte Genomics, where he became Director of Product Development. He also worked with Operon Technologies (acquired by Qiagen), leading product development and commercial strategies. Deval has represented THP on the boards of AcroMetrix (acquired by Life Technologies), Agena Bioscience (acquired by Mesa Laboratories), Akoya Biosciences (NASDAQ:AKYA), Althea Technologies (acquired by Ajinomoto), Applied Precision (acquired by GE), Argonaut Manufacturing Services, Aurora Discovery (acquired by NEXUS Biosystems), Asuragen (acquired by Bio-Techne), Cell Microsystems, Community Bio, Dynex, NEXUS Biosystems (acquired by Brooks Automation), Nimble Therapeutics, Precision NanoSystems (acquired by Danaher), RareCyte, Sage Labs (acquired by Horizon Discovery), and SwitchGear Genomics (acquired by Active Motif). He has been an observer on the boards of Dharmacon (acquired by Fisher Scientific) and Carterra. Dr. Lashkari received a BA with highest honors from the University of California, Berkeley, and a Ph.D. from Stanford University and currently serves on the Stanford Medical School Alumni Board of Governors.
Before joining THP, Rob worked as a Partner at Trinity Life Sciences, a consultancy focused on evidence-based clinical and commercial development strategy across therapeutics, diagnostics, and medical technology sectors. Rob worked as a strategy consultant for a total of 10 years, partnering with emerging biotechnology & medical technology companies as well as large, global organizations to inform key decisions on clinical development, launch strategy, market development, brand lifecycle strategy, and promotional campaign development. Prior to working as a strategy consultant, Rob worked at Telegraph Hill Partners for four years as an Associate, working on market analysis, transaction execution, and portfolio company initiatives. Rob worked as an Associate at Telegraph Hill Partners, an analyst at Seven Hill Partners, a boutique investment banking firm focused on life sciences and technology verticals. Rob represents THP on the boards of Cell Microsystems and Emerging Therapy Solutions. Rob holds a BBA in Finance from the University of Notre Dame and an MBA with honors from UC Berkeley’s Haas School of Business.
Before joining THP in 2009, Alex worked in Business Development in the Oncology/Multiple Sclerosis Group at Genzyme Corporation. At Genzyme, he structured licensing and M&A transactions in the biotechnology and pharmaceuticals space. He also worked as a Portfolio Manager at BlueMountain Capital Management and as an Analyst in Investment Banking at Bank of America Securities. In 2021, he moved to North Carolina from San Francisco to open THP’s Research Triangle office. He has represented THP on the boards of Argonaut Manufacturing Services, Carterra, Cell Microsystems, Community Bio, Dynex Technologies and Teknova (NASDAQ:TKNO). He was a board observer at Agena Bioscience (acquired by Mesa Laboratories).Alex holds an MBA with honors from Kellogg School of Management at Northwestern University and a Bachelor of Science in Economics with a Minor in Molecular and Cellular Biology from Duke University.
Brett is the President and CEO at Verogen Corporation, a sequencing company advancing next-generation sequencing to help unlock the true potential of forensic genomics. He is a scientist by training, earning his Master of Science is Cytogenetics and Molecular Biology from Queensland University of Technology and an MBA from the Warwick Business School. He worked at Applied Biosystems, Invitrogen, Life Tech, Thermo, and as CEO at private equity-run portfolio companies.
Dr. Sims is a Professor at the University of Washington with joint appointments in the departments of Bioengineering and Medicine. He founded Cell Biosciences (now Protein Simple) along with his colleague, Dr. Allbritton in 2002. Drs. Sims, Allbritton and Wang were also founders of Intellego Corporation which became a subsidiary of Amkor Technology and Altis Biosystems. Dr. Sims earned his M.D. degree from Johns Hopkins University followed by a medicine residency at Harvard and fellowships at Stanford.